

From Carolyn Boone, the first patient enrolled in an ARIAD clinical trial of ridaforolimus, to those enrolling in our current Phase 3 SUCCEED trial for the treatment of metastatic soft tissue or bone sarcomas, patients and caregivers are our most important partners. For them and for ARIAD, the quest for knowledge is integral to the fight against cancer.
In addition to our discovery and development programs, we are committed to helping patients, family members, advocates and caregivers find the information and resources they need.

ARIAD’s lead product candidate, ridaforolimus, is a novel, potent mTOR inhibitor in development for multiple oncology indications.